Treatment Breakthroughs in Plaque Psoriasis
.jpg)
OASIS-1: Mirikizumab Improved Moderate-to-Severe Plaque Psoriasis Symptoms Up to 52 Weeks
August 4, 2022
Results from a phase 3 study of mirikizumab showed the IL-23 inhibitor significantly improved symptoms of moderate-to-severe plaque psoriasis, although the developer has since declined to pursue regulatory approval for the potential treatment...
FDA Approves Ustekinumab for Pediatric Psoriatic Arthritis
August 25, 2022The FDA has approved ustekinumab for the treatment of pediatric patients 6 years of age and older with psoriatic arthritis...
Less Painful Citrate-Free Ixekizumab Injection Now Approved
August 22, 2022The FDA has approved a new citrate-free formulation of ixekizumab 80mg/ml injection...
Psoriasis Linked with Higher Risk for Fatty Liver Disease
August 17, 2022Psoriasis is linked with a higher risk for nonalcoholic fatty liver disease (NAFLD) in US outpatients...
Study Examines Drug Survival of Biologics for Patients with Psoriasis
August 10, 2022A recent study published in JAMA Dermatology examined drug survival in common psoriasis biologic medications as proxies for safety and effectiveness...
Risankizumab Improved Psoriasis Symptoms in Patients Who Previously Failed IL-17 Therapy
July 8, 2022A proportion of patients with psoriasis who previously failed interleukin (IL)-17 treatment showed improvement after receiving risankizumab...
